The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group Study AALL0232
Open accessAbstract
Purpose: Survival for children and young adults with high-risk B-acute lymphoblastic leukemia has improved significantly, but 20% to 25% of patients are not cured. Children’s Oncology Group study AALL0232 tested two interventions to improve survival. Patients and Methods: Between January 2004 and January 2011, AALL0232 enrolled 3,154 participants 1 to 30 years old with newly diagnosed high-risk B-acute lymphoblastic leukemia. By using a 2 × 2 factorial design, 2,914 participants were randomly assigned to receive dexamethasone (14 days) versus prednisone (28 days) during induction and high-dose methotrexate versus Capizzi escalating-dose methotrexate plus pegaspargase during interim maintenance 1. Results: Planned interim monitoring showed the superiority of the high-dose methotrexate regimens, which exceeded the predefined boundary and led to cessation of enrollment in January 2011. At that time, participants randomly assigned to high-dose methotrexate during interim maintenance 1 versus those randomly assigned to Capizzi methotrexate had a 5-year event-free survival (EFS) of 82% versus 75.4% (P = .006). Mature final data showed 5-year EFS rates of 79.6% for high-dose methotrexate and 75.2% for Capizzi methotrexate (P = .008). High-dose methotrexate decreased both marrow and CNS recurrences. Patients 1 to 9 years old who received dexamethasone and high-dose methotrexate had a superior outcome compared with those who received the other three regimens (5-year EFS, 91.2% v 83.2%, 80.8%, and 82.1%; P = .015). Older participants derived no benefit from dexamethasone during induction and experienced excess rates of osteonecrosis. Conclusion: High-dose methotrexate is superior to Capizzi methotrexate for the treatment of high-risk B-acute lymphoblastic leukemia, with no increase in acute toxicity. Dexamethasone given during induction benefited younger children but provided no benefit and was associated with a higher risk of osteonecrosis among participants 10 years and older.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Roberts, K. G., Li, Y., Payne-Turner, D., Harvey, R. C., Yang, Y.-L., Pei, D., McCastlain, K., Ding, L., Lu, C., Song, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403088 · Cited by 1,377
Self-citationHunger, S. P., Lu, X., Devidas, M., Camitta, B. M., Gaynon, P. S., Winick, N. J., Reaman, G. H., & Carroll, W. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.8018 · Cited by 1,180
Self-citationSmith, M., Arthur, D., Camitta, B., Carroll, A. J., Crist, W., Gaynon, P., Gelber, R., Heerema, N., Korn, E. L., Link, M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.18 · Cited by 901
Self-citationSilverman, L. B. (2001) · Blood · doi:10.1182/blood.v97.5.1211 · Cited by 865
Borowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., Linda, S., Martin, P. L., Pullen, D. J., Viswanatha, D., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132837 · Cited by 842
Self-citationBiology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update
Pui, C.-H., Carroll, W. L., Meshinchi, S., & Arceci, R. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7405 · Cited by 842
Self-citationSchrappe, M., Reiter, A., Zimmermann, M., Harbott, J., Ludwig, W.-D., Henze, G., Gadner, H., Odenwald, E., & Riehm, H. (2000) · Leukemia · doi:10.1038/sj.leu.2401973 · Cited by 531
Möricke, A., Zimmermann, M., Reiter, A., Henze, G., Schrauder, A., Gadner, H., Ludwig, W. D., Ritter, J., Harbott, J., Mann, G., et al. (2010) · Leukemia · doi:10.1038/leu.2009.257 · Cited by 520
Vora, A., Goulden, N., Wade, R., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., & Richards, S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70600-9 · Cited by 478
Nachman, J. B., Sather, H. N., Sensel, M. G., Trigg, M. E., Cherlow, J. M., Lukens, J. N., Wolff, L., Uckun, F. M., & Gaynon, P. S. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806043382304 · Cited by 445
Mitchell, C. D., Richards, S. M., Kinsey, S. E., Lilleyman, J., Vora, A., Eden, T. O. B., & the Medical Research Council Childhood Leukaemia Working Party (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05509.x · Cited by 418
Mattano, L. A., Sather, H. N., Trigg, M. E., & Nachman, J. B. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.18.3262 · Cited by 399
Self-citationBorowitz, M. J., Wood, B. L., Devidas, M., Loh, M. L., Raetz, E. A., Salzer, W. L., Nachman, J. B., Carroll, A. J., Heerema, N. A., Gastier-Foster, J. M., et al. (2015) · Blood · doi:10.1182/blood-2015-03-633685 · Cited by 362
Self-citationVrooman, L. M., Stevenson, K. E., Supko, J. G., O'Brien, J., Dahlberg, S. E., Asselin, B. L., Athale, U. H., Clavell, L. A., Kelly, K. M., Kutok, J. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2070 · Cited by 315
Seibel, N. L., Steinherz, P. G., Sather, H. N., Nachman, J. B., DeLaat, C., Ettinger, L. J., Freyer, D. R., Mattano, L. A., Hastings, C. A., Rubin, C. M., et al. (2008) · Blood · doi:10.1182/blood-2007-02-070342 · Cited by 312
Self-citationPui, C. H., Pei, D., Sandlund, J. T., Ribeiro, R. C., Rubnitz, J. E., Raimondi, S. C., Onciu, M., Campana, D., Kun, L. E., Jeha, S., et al. (2010) · Leukemia · doi:10.1038/leu.2009.252 · Cited by 293
Kawedia, J. D., Kaste, S. C., Pei, D., Panetta, J. C., Cai, X., Cheng, C., Neale, G., Howard, S. C., Evans, W. E., Pui, C.-H., et al. (2011) · Blood · doi:10.1182/blood-2010-10-311969 · Cited by 261
Balis, F. M., Lester, C. M., Chrousos, G. P., Heideman, R. L., & Poplack, D. G. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.2.202 · Cited by 251
Akslen, L. A., & LiVolsi, V. A. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000415)88:8<1964::aid-cncr27>3.0.co;2-1 · Cited by 231
Vilmer, E., Suciu, S., Ferster, A., Bertrand, Y., Cavé, H., Thyss, A., Benoit, Y., Dastugue, N., Fournier, M., Souillet, G., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401960 · Cited by 204
Asparaginase May Influence Dexamethasone Pharmacokinetics in Acute Lymphoblastic Leukemia
Yang, L., Panetta, J. C., Cai, X., Yang, W., Pei, D., Cheng, C., Kornegay, N., Pui, C., & Relling, M. V. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8404 · Cited by 160
Predicting relapse risk in childhood acute lymphoblastic leukaemia
Teachey, D. T., & Hunger, S. P. (2013) · British Journal of Haematology · doi:10.1111/bjh.12442 · Cited by 118
Self-citationKaspers, G. J. L., Veerman, A. J. P., Popp‐Snijders, C., Lomecky, M. Z., van Zantwijk, C. H., Swinkels, L. M. J. W., van Wering, E. R., & Pieters, R. (1996) · Medical and Pediatric Oncology · Cited by 96
Pound, C., Clark, C. G., Ni, A., Athale, U. H., Lewis, V. A., & Halton, J. (2012) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e318257fdac · Cited by 58
Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia
Petersen, K. B., Jusko, W. J., Rasmussen, M., & Schmiegelow, K. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0602-3 · Cited by 37
Cited by
Malard, F., & Mohty, M. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33018-1 · Cited by 773
Pediatric acute lymphoblastic leukemia
Inaba, H., & Mullighan, C. G. (2020) · Haematologica · doi:10.3324/haematol.2020.247031 · Cited by 696
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
Gu, Z., Churchman, M. L., Roberts, K. G., Moore, I., Zhou, X., Nakitandwe, J., Hagiwara, K., Pelletier, S., Gingras, S., Berns, H., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0315-5 · Cited by 603
Self-citationPediatric acute lymphoblastic leukemia: where are we going and how do we get there?
Pui, C.-H., Mullighan, C. G., Evans, W. E., & Relling, M. V. (2012) · Blood · doi:10.1182/blood-2012-05-378943 · Cited by 500
Stock, W., Luger, S. M., Advani, A. S., Yin, J., Harvey, R. C., Mullighan, C. G., Willman, C. L., Fulton, N., Laumann, K. M., Malnassy, G., et al. (2019) · Blood · doi:10.1182/blood-2018-10-881961 · Cited by 488
Self-citation
Metadata
- Authors
- Larsen, E. C., Devidas, M., Chen, S., Salzer, W. L., Raetz, E. A., Loh, M. L., Mattano, L. A., Cole, C., Eicher, A., Haugan, M., Sorenson, M., Heerema, N. A., Carroll, A. A., Gastier-Foster, J. M., Borowitz, M. J., Wood, B. L., Willman, C. L., Winick, N. J., Hunger, S. P., & Carroll, W. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-07-10
- Volume
- 34
- Issue
- 20
- Pages
- 2380-2388
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2342769258
- Cited by
- 379
- References
- 30
- FWCI
- 36.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.